SoBat Kanker smartphone application to improve oral chemotherapy adherence among cancer patients in Indonesia: Development, usability, and feasibility pilot study
Penulis/Author
Atika Wahyu Puspitasari (1); Prof. Dr. Susi Ari Kristina, S.Farm., M.Kes., Apt. (2); Prof. Dr. Satibi, S.Si., M.Si. Apt. (3); Prof. Dra. Raden Ajeng Yayi Suryo Prabandari, M.Si., Ph.D. (4)
Tanggal/Date
2024
Kata Kunci/Keyword
Abstrak/Abstract
This study aimed to design, develop, and evaluate the usability and feasibility of the SoBat Kanker smartphone
application to improve oral chemotherapy adherence among Indonesian cancer patients. This mixed-methods study
was conducted from January 2022 to April 2023 at the National Cancer Centre, Jakarta. This study was conducted in
two sequential phases: Phase I focused on developing the app using a user-centered design approach and evaluating
the app using a System Usability Scale (SUS), and Phase II focused on the feasibility test of the app using one group
pre-post-test design. Medication adherence was measured to test the feasibility of use using the oral chemotherapy
adherence scale. The SoBat Kanker app was successfully developed in Bahasa Indonesia and was available in the
Google Play Store. The app features consisted of a list of patient medications and alarm reminders for taking a drug,
chatting with a pharmacist, medication information, and a diary with reminders to keep appointments related to
refilling prescriptions and attending the hospital. The average system usability (SUS) score was 85.33, indicating
grade A and excellent system usability. Preliminary adherence outcome measure showed significant adherence
improvement in pre-post intervention at 6-week follow-up (p < 0.001). Smartphone application programs may be
useful and support cancer patients taking medication as prescribed. In this usability and feasibility study, the SoBat
Kanker app showed acceptable, easy-to-use, and improved medication adherence. However, further studies are
necessary for efficacy testing in a large-scale randomized controlled trial.
